1.Prediction and verification of the mechanism of Chaiqi yigan granules improving hepatocellular carcinoma
Guiping MA ; Yuanjie ZHANG ; Yichi ZHOU ; Jinzhen LYU ; Conghui WANG ; Fenping LU ; Bowen LIU ; Yun RAN ; Shiping HU
China Pharmacy 2026;37(5):620-625
OBJECTIVE To predict and validate the mechanisms of Chaiqi yigan granules (CQYG) improving hepatocellular carcinoma (HCC). METHODS The signaling pathways of CQYG intervention in HCC were predicted using network pharmacology. A mice model of transplanted hepatocellular carcinoma was established by injecting H22 hepatoma cells into the axilla. Successfully modeled mice were randomly divided into model group (normal saline), sorafenib group (positive control, 50 mg/kg), and CQYG low-, medium- and high-dose groups (24.83, 49.66, 99.32 g/kg), with 10 mice in each group. Mice in each group were administered the corresponding drug solution or normal saline intragastrically, once a day, for 14 consecutive days. After last administration, pathological morphological changes in the tumor tissues of mice were observed in each group. Immunohistochemical staining was performed to detect the expression of the nuclear proliferation antigen Ki-67 in tumor tissues of mice. Western blot assay was used to measure the expression of proteins related to epithelial-mesenchymal transition (EMT) [N-cadherin, E-cadherin, Vimentin, matrix metalloproteinase 7 (MMP7)] and the mitogen-activated protein kinase (MAPK) signaling pathway [p38 MAPK, phosphorylated p38 MAPK, c-Jun N-terminal kinase (JNK), phosphorylated JNK, extracellular regulated protein kinase 1/2 (ERK1/2), phosphorylated ERK1/2] in tumor tissue of mice. RESULTS Network pharmacology analysis revealed that metabolic pathways, pathways in cancer, and the MAPK signaling pathway were key signaling pathways through which CQYG exert their anti-hepatocellular carcinoma effects. In animal experiments, the tumor tissues of mice in the model group exhibited dense tumor cells and vigorous growth. Compared with model group, CQYG high-dose group showed a decreased density of tumor cells in the tumor tissues of mice. Moreover, the expression levels of Ki-67, N-cadherin, MMP7 and Vimentin proteins, along with the phosphorylation levels of ERK1/2 and JNK proteins, were all significantly reduced ( P <0.05). The expression level of E-cadherin protein was significantly increased ( P <0.05), the phosphorylation level of p38 MAPK protein was increased, the difference was not statistically significant ( P >0.05). CONCLUSIONS CQYG can inhibit EMT by regulating the MAPK signaling pathway, thereby suppressing tumor cell invasion and metastasis and ultimately exerting a therapeutic effect in improving HCC.
2.Deep transcranial magnetic stimulation coil design and multi-objective slime mould algorithm.
Hui XIONG ; Jibin ZHU ; Jinzhen LIU
Journal of Biomedical Engineering 2025;42(4):716-723
The therapeutic effects of transcranial magnetic stimulation (TMS) are closely related to the structure of the stimulation coil. Based on this, this study designed an A-word coil and proposed a multi-strategy fusion multi-objective slime mould algorithm (MSSMA) aimed at optimizing the stimulation depth, focality, and intensity of the coil. MSSMA significantly improved the convergence and distribution of the algorithm by integrating a dual-elite guiding mechanism, a hyperbolic tangent control strategy, and a hybrid polynomial mutation strategy. Furthermore, compared with other stimulation coils, the novel coil optimized by the MSSMA demonstrates superior performance in terms of stimulation depth. To verify the optimization effects, a magnetic field measurement system was established, and a comparison of the measurement data with simulation data confirmed that the proposed algorithm could effectively optimize coil performance. In summary, this study provides a new approach for deep TMS, and the proposed algorithm holds significant reference value for multi-objective engineering optimization problems.
Algorithms
;
Transcranial Magnetic Stimulation/instrumentation*
;
Equipment Design
;
Humans
3.Report of 6 cases of lymphoproliferative disorders after liver transplantation
Hui ZHANG ; Yandong SUN ; Feng WANG ; Dan LIU ; Bin ZHUANG ; Jianhong WANG ; Dahong TENG ; Jinzhen CAI
Chinese Journal of Organ Transplantation 2025;46(2):161-165
This study reports the diagnosis and treatment of six cases of post-transplant lymphoproliferative disorder (PTLD) in liver transplant recipients, confirmed at the Affiliated Hospital of Qingdao University between August 2017 and May 2023. The report includes details on anti-rejection therapy, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, imaging findings, histopathological results, treatment courses, and prognoses. By summarizing the clinical experience in the diagnosis and management of PTLD following liver transplantation, this study aims to provide valuable insights and references for the clinical diagnosis and treatment of this condition.
4.Nine cases report of lymphoproliferative diseases after liver transplantation
Hongjing DONG ; Qiuju TIAN ; Qun ZHANG ; Fengchao LIU ; Jinzhen CAI ; Wei RAO
Chinese Journal of Organ Transplantation 2025;46(11):797-800
This study retrospectively reviewed the clinical data of 9 recipients with post-transplant lymphoproliferative disorder (PTLD) after liver transplantation admitted to the Organ Transplantation Center of the Affiliated Hospital of Qingdao University from January 2020 to June 2024, and summarized their clinical manifestations, pathological features, treatment regimens, and prognostic conditions, so as to provide a reference for clinical diagnosis and treatment.
5.Analysis of curative effect of liver transplantation in patients with polycystic liver disease
Anhua DONG ; Yanfen DAI ; Yandong SUN ; Hui ZHANG ; Jinzhen CAI ; Yuan LIU
Chinese Journal of Hepatobiliary Surgery 2025;31(4):253-257
Objective:To evaluate the treatment outcome of liver transplantation for patients with polycystic liver disease (PLD).Methods:Clinical data of 28 PLD patients admitted to the Affiliated Hospital of Qingdao University from May 2014 to November 2023 were retrospectively analyzed, including 10 males and 18 females, aged (50.4±6.6) years. Patients were divided into liver transplantation group ( n=15) and non-liver transplantation group ( n=13). In the liver transplantation group, we analyzed seve-ral critical parameters including methods of liver transplantation, intra-abdominal fluid volume, intraoperative blood loss, intraoperative red blood cell transfusion requirements, and postoperative complications. The prognosis of the two groups were also compared. Results:Among the 28 patients with PLD, 15 underwent liver transplantation, including 11 classic in situ liver transplantations, one modified back-to-back liver transplantation, and three liver-kidney combined transplantations. The 15 patients had 2 000 (300, 4 000) ml of abdominal fluid, 1 000 (600, 2 000) ml of intraoperative blood loss, and 8.0 (6.0, 17.0) U of red blood cells transfused during the operation. Postoperative complications occurred in eight cases, with four of which were managemed successfully, and the other four died. The 1-, 5-, and 10-year survival rates of after liver transplantation were 80.0%, 80.0%, and 73.3%, respectively. The 1-, 5-, and 10-year survival rates of patients with PLD without liver transplantation were 69.2%, 46.2%, and 38.5%, respectively. The difference between the two groups was statistically significant ( χ2=3.91, P=0.048). Conclusion:Liver transplantation is a treatment option for patients with PLD, with a better long-term survival compared to patients without liver transplantation.
6.Analysis of curative effect of liver transplantation in patients with polycystic liver disease
Anhua DONG ; Yanfen DAI ; Yandong SUN ; Hui ZHANG ; Jinzhen CAI ; Yuan LIU
Chinese Journal of Hepatobiliary Surgery 2025;31(4):253-257
Objective:To evaluate the treatment outcome of liver transplantation for patients with polycystic liver disease (PLD).Methods:Clinical data of 28 PLD patients admitted to the Affiliated Hospital of Qingdao University from May 2014 to November 2023 were retrospectively analyzed, including 10 males and 18 females, aged (50.4±6.6) years. Patients were divided into liver transplantation group ( n=15) and non-liver transplantation group ( n=13). In the liver transplantation group, we analyzed seve-ral critical parameters including methods of liver transplantation, intra-abdominal fluid volume, intraoperative blood loss, intraoperative red blood cell transfusion requirements, and postoperative complications. The prognosis of the two groups were also compared. Results:Among the 28 patients with PLD, 15 underwent liver transplantation, including 11 classic in situ liver transplantations, one modified back-to-back liver transplantation, and three liver-kidney combined transplantations. The 15 patients had 2 000 (300, 4 000) ml of abdominal fluid, 1 000 (600, 2 000) ml of intraoperative blood loss, and 8.0 (6.0, 17.0) U of red blood cells transfused during the operation. Postoperative complications occurred in eight cases, with four of which were managemed successfully, and the other four died. The 1-, 5-, and 10-year survival rates of after liver transplantation were 80.0%, 80.0%, and 73.3%, respectively. The 1-, 5-, and 10-year survival rates of patients with PLD without liver transplantation were 69.2%, 46.2%, and 38.5%, respectively. The difference between the two groups was statistically significant ( χ2=3.91, P=0.048). Conclusion:Liver transplantation is a treatment option for patients with PLD, with a better long-term survival compared to patients without liver transplantation.
7.Report of 6 cases of lymphoproliferative disorders after liver transplantation
Hui ZHANG ; Yandong SUN ; Feng WANG ; Dan LIU ; Bin ZHUANG ; Jianhong WANG ; Dahong TENG ; Jinzhen CAI
Chinese Journal of Organ Transplantation 2025;46(2):161-165
This study reports the diagnosis and treatment of six cases of post-transplant lymphoproliferative disorder (PTLD) in liver transplant recipients, confirmed at the Affiliated Hospital of Qingdao University between August 2017 and May 2023. The report includes details on anti-rejection therapy, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, imaging findings, histopathological results, treatment courses, and prognoses. By summarizing the clinical experience in the diagnosis and management of PTLD following liver transplantation, this study aims to provide valuable insights and references for the clinical diagnosis and treatment of this condition.
8.Nine cases report of lymphoproliferative diseases after liver transplantation
Hongjing DONG ; Qiuju TIAN ; Qun ZHANG ; Fengchao LIU ; Jinzhen CAI ; Wei RAO
Chinese Journal of Organ Transplantation 2025;46(11):797-800
This study retrospectively reviewed the clinical data of 9 recipients with post-transplant lymphoproliferative disorder (PTLD) after liver transplantation admitted to the Organ Transplantation Center of the Affiliated Hospital of Qingdao University from January 2020 to June 2024, and summarized their clinical manifestations, pathological features, treatment regimens, and prognostic conditions, so as to provide a reference for clinical diagnosis and treatment.
9.Successful trans-blood liver transplantation after artificial liver support therapy in a patient with hepatic coma: A case report
Shuang SUN ; Jinquan LIU ; Shuai FENG ; Shuxian WANG ; Xiangmei XU ; Deshu DAI ; Jianhong WANG ; Jinzhen CAI ; Chuanshen XU
Journal of Clinical Hepatology 2024;40(4):791-793
This article reports a patient with hepatic coma who underwent artificial liver support therapy and liver transplantation successfully, and the patient recovered well in the later stage after active treatment. This article also discusses the timing of liver transplantation.
10.Decision-making experience of patients with abdominoplasty: a qualitative study
Hui WENG ; Chenzi XU ; Ming PANG ; Jinzhen REN ; Zhen WEI ; Handou LI ; Xuan HAO ; Zhirong LIU
Chinese Journal of Plastic Surgery 2024;40(11):1221-1227
Objective:To explore the decision-making experience of patients undergoing abdominoplasty in our country.Methods:A semi-structured interview was conducted with patients suffering from postpartum abdominal wall laxity who were treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from June to August 2023. The data were sort and analyzed using the Clolaizzi 7-step analysis method for thematic description.Results:A total of 15 patients, aged 29-53 years, were included in the study. 11 had a college education or higher, while 4 had less than a college education.Thirteen were married and two were divorced. According to the interview data, four themes were extracted: (1) negative perceptual experiences; (2) decision-making dilemmas; (3) peer support; (4) a physician-led decision-making model. According to the interview, the main decision-making dilemma faced by patients with postpartum abdominal wall laxity was lack of information and family support, and the support they get was mostly from information exchange among patients, and they had insufficient cognition of surgical knowledge, improvement degree and risk, and low participation in clinical decision making.Conclusion:Patients with postpartum abdominal wall laxity in China have an urgent psychological need for abdominoplasty, but there are many factors that have adverse effects on their decision-making experience.

Result Analysis
Print
Save
E-mail